Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-06-24 18:06:22 ET · period of report 2026-06-22 · accession 0001470831-26-000635 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-24 18:06 | 2026-06-22 | BBIO | Valantine Hannah | Dir | A - Grant | $0.00 | +3,990 | 11.5K | +53% | $0 |
| DT | 2026-06-24 18:06 | 2026-06-22 | BBIO | Valantine Hannah | Dir | M - OptEx | $41.73 | +2,808 | 14.3K | +25% | +$117.2K |
| DMT | 2026-06-24 18:06 | 2026-06-22+ | BBIO | Valantine Hannah | Dir | S - Sale+OE | $68.25 | -5,004 | 9,259 | -35% | -$341.5K |
| DT | 2026-06-24 18:06 | 2026-06-22 | BBIO | Valantine Hannah | Dir | A - Grant | $0.00 | +5,277 | 5,277 | New | $0 |
| DT | 2026-06-24 18:06 | 2026-06-22 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -2,808 | 5,617 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-22 | A | A | 3,990 | $0.00 | 11,455 | D | — | — | (F1) Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. (F2) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2026-06-22 | M | A | 2,808 | $41.73 | 14,263 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-22 | S | D | 2,808 | $68.00 | 11,455 | D | — | — | (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. |
| 4 | Common | Common Stock | 2026-06-23 | S | D | 2,196 | $68.57 | 9,259 | D | — | — | (F3) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | A | A | 5,277 | $0.00 | 5,277 | D | $68.92 · — to 2036-06-21 | 5,277 Common Stock | (F4) The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-06-22 | M | D | 2,808 | $0.00 | 5,617 | D | $41.73 · — to 2035-06-19 | 2,808 Common Stock | (F5) One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. |